drugset
drugset / Trial / NCT04850040

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

NCT04850040 ↗

Phase 2 Unknown 15 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, single-center, clinical research.This trial will explore the efficacy and safety of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.

Timeline

Start
2021-05-06
Primary completion
2022-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 —
Subject Rivoceranib Small molecule 250 mg Oral

Indications

hepatocellular carcinoma